section in the explanatory material for the old guidelines erased the requirement for separate facilities. The latest guidelines also remove the secondary approval step for working with ES cells: a local review committee must still approve the work, but researchers then need only notify the science ministry of this.
Yet some burdensome restrictions remain, says Suemori. For example, the notification must include "word-for-word" minutes of the local review committee's meeting.
And the two-stage approval pro cess remains for deriving new cell lines. Norio Nakatsuji, director of Kyoto University's Institute for Integrated CellMaterial Sciences, who created all five of Japan's human ES-cell lines, has given up plans to make any more. "I would summarize the change as being from absurd to excessively strict," he says. "These irrational guidelines have done and will probably continue to do great damage to all related research fields in Japan. " Last December, Yamanaka was widely quoted for remarks made at a science-ministry assembly in which he appraised Japan's 2008 record against other iPS-cell research groups, mostly in the United States: "One win, and about 10 losses, " he said.
The new regulations were pushed through by the Council for Science and Technology Policy, a 15-person group chaired by the prime minister that stands as the country's highest science-policy body. Junichi Iwata, of the science ministry's life-science division, says the changes were targeted at the use of human ES cells and not their derivation, explaining that only two groups are licensed to derive such cells. Asked why the reform didn't go further in addressing researchers' criticisms, he says: "The new guidelines just went into effect, so we'll see how things go. If need be, we'll change them again. " But it might be too late to make a difference. Most of Japan's stem-cell researchers have already been pushed into iPS-cell research through targeted funding programmes and are unlikely to go back to the ES-cell basics. "I do not expect a dramatic increase in ES-cell research, " says Shin-Ichi Nishikawa, a stem-cell researcher at the RIKEN Center for Developmental Biology in Kobe.
Suemori likewise sees little change and fading hope. "It will be very difficult for us to catch up now, " he says.
